NeoGenomics, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own0.80% Shs Outstand124.70M Perf Week-9.46%
Market Cap2.38B Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float122.24M Perf Month6.47%
Income-144.30M PEG- EPS next Q-0.15 Inst Own90.80% Short Float / Ratio5.31% / 6.03 Perf Quarter86.81%
Sales509.70M P/S4.67 EPS this Y-151.90% Inst Trans-4.07% Short Interest6.49M Perf Half Y93.13%
Book/sh8.00 P/B2.17 EPS next Y22.10% ROA-8.10% Target Price20.18 Perf Year-2.61%
Cash/sh3.19 P/C5.43 EPS next 5Y1.30% ROE-14.00% 52W Range6.00 - 19.51 Perf YTD85.40%
Dividend- P/FCF- EPS past 5Y-45.90% ROI-9.30% 52W High-12.20% Beta1.12
Dividend %- Quick Ratio6.50 Sales past 5Y16.20% Gross Margin36.90% 52W Low185.51% ATR0.99
Employees2100 Current Ratio6.70 Sales Q/Q10.30% Oper. Margin-30.90% RSI (14)51.75 Volatility4.75% 5.78%
OptionableYes Debt/Eq0.54 EPS Q/Q46.60% Profit Margin-28.30% Rel Volume1.36 Prev Close17.34
ShortableYes LT Debt/Eq0.54 EarningsFeb 23 BMO Payout- Avg Volume1.08M Price17.13
Recom2.20 SMA20-4.19% SMA5016.53% SMA20058.84% Volume1,027,766 Change-1.21%
Feb-24-23Upgrade The Benchmark Company Hold → Buy $20
Feb-01-23Upgrade Needham Hold → Buy $15
Aug-26-22Downgrade The Benchmark Company Buy → Hold
Aug-22-22Downgrade Needham Buy → Hold
Jun-03-22Initiated Piper Sandler Overweight $13
Mar-29-22Downgrade Stephens Overweight → Equal-Weight $34 → $16
Mar-29-22Downgrade BofA Securities Buy → Neutral $25 → $18
Jan-18-22Resumed Stephens Overweight $40
Dec-16-21Initiated Cowen Outperform $42
Nov-05-21Downgrade Morgan Stanley Overweight → Equal-Weight
Show Previous Ratings
Mar-27-23 07:00AM
Mar-22-23 08:00AM
Mar-21-23 08:06AM
Mar-19-23 06:24AM
Mar-16-23 07:00AM
07:00AM Loading…
Mar-13-23 07:00AM
Feb-28-23 07:00AM
Feb-23-23 03:34PM
Feb-06-23 07:00AM
Dec-12-22 09:55AM
Dec-05-22 07:50PM
07:35PM Loading…
Nov-21-22 07:00AM
Nov-18-22 09:20AM
Nov-11-22 05:36PM
Nov-08-22 08:45AM
Nov-07-22 04:35PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-28-22 07:00AM
Oct-13-22 07:00AM
Oct-12-22 07:44AM
Sep-30-22 10:45AM
Sep-07-22 02:00AM
11:51AM Loading…
Aug-22-22 11:51AM
Aug-16-22 05:00PM
Aug-10-22 09:40AM
Aug-09-22 08:25AM
Aug-03-22 10:00AM
Aug-02-22 10:01AM
Jul-28-22 07:05PM
Jul-21-22 07:00AM
Jul-15-22 04:05PM
Jul-06-22 11:47PM
Jun-27-22 08:33AM
Jun-21-22 02:00AM
Jun-20-22 07:39AM
Jun-13-22 11:13AM
Jun-03-22 04:05PM
May-16-22 07:00AM
May-10-22 02:00AM
May-09-22 07:00AM
May-05-22 04:05PM
Apr-27-22 08:45AM
Apr-25-22 07:00AM
Apr-20-22 03:01PM
Apr-11-22 10:00AM
Apr-08-22 04:05PM
Mar-30-22 07:21AM
Mar-29-22 04:14PM
Mar-28-22 04:58PM
Mar-17-22 03:00AM
Mar-02-22 04:05PM
Feb-27-22 10:59PM
Feb-23-22 08:45AM
Feb-14-22 07:00AM
Feb-11-22 02:00AM
Feb-08-22 07:00AM
Feb-04-22 07:56AM
Feb-03-22 05:38PM
Feb-02-22 04:05PM
Feb-01-22 01:38PM
Jan-24-22 07:00AM
Jan-11-22 07:00AM
Dec-29-21 03:58PM
Dec-13-21 02:00AM
Dec-11-21 06:38AM
Dec-10-21 07:00AM
Dec-07-21 12:15AM
Nov-30-21 07:00AM
Nov-23-21 11:11AM
Nov-10-21 07:00AM
Nov-08-21 05:00AM
Nov-06-21 01:30PM
Nov-04-21 10:55AM
Oct-28-21 03:05PM
Oct-19-21 02:00AM
Oct-13-21 04:20PM
Oct-12-21 04:05PM
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TETRAULT LYNN A.DirectorMay 18Option Exercise7.273,33424,23839,111May 20 05:08 PM
Bonello WilliamChief Financial OfficerApr 28Option Exercise7.525,72743,067191,548May 02 05:46 PM